Quote:From my AI thoughts
The most impressive update was the ctDNA data. Among 28 evaluable CLOVER patients, the median decline was approximately 86%, with a roughly 90% decline at the 700 mg dose compared with 80% at 350 mg. The apparent dose response makes the biological signal more compelling.
So last May there were "28 evaluable CLOVER patients" who showed great ctDNA data. But then by September, max after 3-4 months, there was only 22 patients remaining on the study. Did your AI address the significance/implications of this discovery?
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.